BRPI0811930B8 - métodos e kit diagnóstico ou prognóstico de lúpus em um indivíduo - Google Patents

métodos e kit diagnóstico ou prognóstico de lúpus em um indivíduo

Info

Publication number
BRPI0811930B8
BRPI0811930B8 BRPI0811930A BRPI0811930A BRPI0811930B8 BR PI0811930 B8 BRPI0811930 B8 BR PI0811930B8 BR PI0811930 A BRPI0811930 A BR PI0811930A BR PI0811930 A BRPI0811930 A BR PI0811930A BR PI0811930 B8 BRPI0811930 B8 BR PI0811930B8
Authority
BR
Brazil
Prior art keywords
lupus
methods
diagnostic
individual
genetic variations
Prior art date
Application number
BRPI0811930A
Other languages
English (en)
Portuguese (pt)
Inventor
Hom Geoffrey
Royal Graham Robert
w behrens Timothy
A Ortmann Ward
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0811930A2 publication Critical patent/BRPI0811930A2/pt
Publication of BRPI0811930B1 publication Critical patent/BRPI0811930B1/pt
Publication of BRPI0811930B8 publication Critical patent/BRPI0811930B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2533/00—Reactions characterised by the enzymatic reaction principle used
    • C12Q2533/10—Reactions characterised by the enzymatic reaction principle used the purpose being to increase the length of an oligonucleotide strand
    • C12Q2533/101—Primer extension
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Theoretical Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0811930A 2007-05-21 2008-05-21 métodos e kit diagnóstico ou prognóstico de lúpus em um indivíduo BRPI0811930B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93915607P 2007-05-21 2007-05-21
US1328307P 2007-12-12 2007-12-12
PCT/US2008/064430 WO2008144761A2 (en) 2007-05-21 2008-05-21 Methods and compositions for identifying and treating lupus

Publications (3)

Publication Number Publication Date
BRPI0811930A2 BRPI0811930A2 (pt) 2014-11-25
BRPI0811930B1 BRPI0811930B1 (pt) 2019-11-05
BRPI0811930B8 true BRPI0811930B8 (pt) 2021-05-25

Family

ID=40122294

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811930A BRPI0811930B8 (pt) 2007-05-21 2008-05-21 métodos e kit diagnóstico ou prognóstico de lúpus em um indivíduo

Country Status (14)

Country Link
US (1) US20110046094A1 (enExample)
EP (3) EP2612924B1 (enExample)
JP (4) JP5728226B2 (enExample)
KR (4) KR101729431B1 (enExample)
CN (3) CN104593488B (enExample)
AU (1) AU2008254582A1 (enExample)
BR (1) BRPI0811930B8 (enExample)
CA (1) CA2690608C (enExample)
ES (1) ES2661249T3 (enExample)
HK (1) HK1255086A1 (enExample)
IL (1) IL201949A0 (enExample)
MX (3) MX343167B (enExample)
RU (1) RU2009147281A (enExample)
WO (1) WO2008144761A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343167B (es) * 2007-05-21 2016-10-26 Genentech Inc * Metodos y composiciones para identificar y tratar lupus.
BRPI0913778A2 (pt) * 2008-09-26 2015-10-20 Genentech Inc "métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico"
US20100105061A1 (en) * 2008-10-29 2010-04-29 University Of Southern California Autoimmune genes identified in systemic lupus erythematosus (sle)
EP2403959A1 (en) * 2009-03-03 2012-01-11 Merck Serono S.A. Bank1 related snps and sle and/or ms susceptibility
CA2777055C (en) * 2009-10-07 2021-04-06 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
KR20130009784A (ko) * 2010-03-01 2013-01-23 알렉시온 파마슈티칼스, 인코포레이티드 악성 위축성 구진증을 치료하는 방법 및 조성물
US20140112913A1 (en) * 2011-02-10 2014-04-24 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
US20130317006A1 (en) 2012-05-24 2013-11-28 Amy Yasko Use of polymorphisms for identifying individuals at risk of developing autism
WO2015081052A1 (en) 2013-11-27 2015-06-04 Yasko Amy Use of polymorphisms for identifying individuals at risk of developing autism
EP3314015B1 (en) * 2015-06-24 2024-07-31 Oxford BioDynamics PLC Detection of chromosome interactions
CN110459312B (zh) * 2018-05-07 2024-01-12 深圳华大生命科学研究院 类风湿性关节炎易感位点及其应用
EP4076671A4 (en) * 2019-12-18 2024-04-17 The Children's Hospital Of Philadelphia Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same
KR20240021336A (ko) 2022-08-09 2024-02-19 심재홍 수액 채취장치의 냉각기 구조
CN116030889B (zh) * 2023-02-16 2026-01-02 复旦大学 一种线粒体异质性分布中分配差异率计算的模型化方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683203A (en) * 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DK0546073T3 (da) * 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CA2255774C (en) 1996-05-29 2008-03-18 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
WO2001092579A2 (en) 2000-05-30 2001-12-06 Pe Corporation (Ny) Methods for detecting target nucleic acids using coupled ligation and amplification
US6900016B1 (en) * 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
CA2426540A1 (en) * 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
US7205106B1 (en) 2001-07-20 2007-04-17 Roche Molecular Systems, Inc. Association of polymorphisms in IL4-related genes with autoimmune disease
JP2003061677A (ja) * 2001-08-28 2003-03-04 Olympus Optical Co Ltd 全身性エリテマトーデスの感受性遺伝子およびその使用
US20030119004A1 (en) * 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
IL163600A0 (en) * 2002-03-01 2005-12-18 Ravgen Inc Methods for detection of genetic disorders
JP2006521812A (ja) 2003-03-18 2006-09-28 アプレラ コーポレイション 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用
WO2005086872A2 (en) * 2004-03-10 2005-09-22 Celera, An Applera Corporation Business Ptpn22 polymorphisms in diagnosis and therapy
EP1863927A2 (en) * 2005-03-15 2007-12-12 Ares Trading S.A. Compositions and methods for treating and diagnosing inflammatory disorders
CA2614455A1 (en) 2005-08-05 2007-02-15 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
MX343167B (es) * 2007-05-21 2016-10-26 Genentech Inc * Metodos y composiciones para identificar y tratar lupus.
BRPI0913778A2 (pt) * 2008-09-26 2015-10-20 Genentech Inc "métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico"

Also Published As

Publication number Publication date
CN104593488B (zh) 2018-06-12
KR101729431B1 (ko) 2017-04-21
KR20170042831A (ko) 2017-04-19
MX378733B (es) 2025-03-10
KR20150133861A (ko) 2015-11-30
EP3318643A2 (en) 2018-05-09
HK1255086A1 (en) 2019-08-02
BRPI0811930B1 (pt) 2019-11-05
JP2015164426A (ja) 2015-09-17
KR101947093B1 (ko) 2019-02-12
JP2018126146A (ja) 2018-08-16
HK1209459A1 (en) 2016-04-01
KR20100021612A (ko) 2010-02-25
WO2008144761A2 (en) 2008-11-27
HK1189246A1 (en) 2014-05-30
EP2612924B1 (en) 2017-12-20
CN104593488A (zh) 2015-05-06
EP2612924A2 (en) 2013-07-10
RU2009147281A (ru) 2011-06-27
MX2009012531A (es) 2009-12-03
JP6080059B2 (ja) 2017-02-15
CA2690608C (en) 2020-07-21
JP2010528590A (ja) 2010-08-26
WO2008144761A3 (en) 2009-07-02
JP5728226B2 (ja) 2015-06-03
KR101651678B1 (ko) 2016-08-26
BRPI0811930A2 (pt) 2014-11-25
CN103298950B (zh) 2015-01-21
EP3318643A3 (en) 2018-06-20
JP2017035088A (ja) 2017-02-16
CA2690608A1 (en) 2008-11-27
KR20190015629A (ko) 2019-02-13
MX343167B (es) 2016-10-26
MX353428B (es) 2018-01-12
ES2661249T3 (es) 2018-03-28
IL201949A0 (en) 2010-06-16
CN103298950A (zh) 2013-09-11
EP2612924A3 (en) 2013-10-23
EP2158335A2 (en) 2010-03-03
AU2008254582A1 (en) 2008-11-27
US20110046094A1 (en) 2011-02-24
CN108753946A (zh) 2018-11-06

Similar Documents

Publication Publication Date Title
BRPI0811930B8 (pt) métodos e kit diagnóstico ou prognóstico de lúpus em um indivíduo
MX350533B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
GB201009641D0 (en) Methods of monitoring conditions by sequence analysis
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
WO2008109423A8 (en) Multigene assay to predict outcome in an individual with glioblastoma
DE602006019898D1 (de) Chromosomenanalyse mittels molekularer karyotypisierung
IN2014CN01787A (enExample)
WO2011046614A3 (en) Methods and systems for phylogenetic analysis
NZ620799A (en) Molecular diagnostic test for cancer
GB2451985A (en) Sepsis detection microarray
ATE512365T1 (de) Map-2 proteolytische produkte als diagnostische biomarker fur neuralen verletzungen
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
BRPI0919882A8 (pt) Métodos para avaliar padrões de rna
BRPI0607753A2 (pt) método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml
MX2013006669A (es) Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica.
GB2478441A (en) Lung cancer biomarkers and uses thereof
HK1205764A1 (en) Tuberculosis biomarkers and uses thereof
WO2011133949A3 (en) Genetic risk analysis in reward deficiency syndrome
MX2010005060A (es) Identificacion y mapeo a base de microarreglos de adn de puntos de ruptura de translocacion equilibrados.
MX2011008323A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
WO2008103971A3 (en) Prostate cancer survival and recurrence
WO2015070191A3 (en) Systems and methods for detection of genomic variants
EP3219813A3 (en) Methods for treating, diagnosing, and monitoring lupus
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment
WO2019078684A3 (ko) 감각신경성 난청 진단을 위한 마커 tmem43 및 그의 용도

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF